Sophia Genetics is a biotechnology company that specializes in the application of artificial intelligence and data analytics to genomic medicine. By harnessing advanced algorithms and a robust cloud-based platform, the company empowers hospitals and healthcare institutions to interpret and analyze genomic data more effectively. Their focus is on enhancing precision medicine by enabling better diagnosis and treatment options for patients with various genetic diseases and cancers. Through collaboration with healthcare providers, Sophia Genetics aims to improve patient outcomes by integrating genomic insights into clinical workflows, ultimately driving innovation in the field of personalized medicine.
Shares of CrowdStrike Holdings, Inc. (NASDAQ: CRWD) shares surged 24.4% to $370.27 in pre-market trading after the company reported better-than-expected fourth-quarter earnings and revenues and issued upbeat guidance for FY25.
Sophia Genetics (NASDAQ:SOPH) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
As of Jan. 22, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance.
